Proteus snaps up $30M to take on heart failure
Proteus Biomedical Inc., a company developing microscopic electromechanical devices capable of one day treating or preventing congestive heart failure, brought in more than $30 million in its first call for fourth round financing. It’s original goal was $28.6 million, but CEO Andrew Thompson says the company is looking for even more money before the round’s second close, VentureWire reported.
The Redwood City, Calif.-based biotech firm is looking to strike out ahead of its competitors, CardioMEMS Inc…. Continue Reading
Mobile company UIEvolution raises Intel funding as it spins off from Square Enix
UIEvolution, a mobile technology startup that was acquired by video game maker Square Enix in 2004, is making a second go-round as an independent company, and it just raised funding from Intel Capital. The company isn’t disclosing the amount, but the Puget Sound Business Journal reports that it was $5 million.
The Bellevue, Wash. startup offers a number of tools for the creation and delivery of mobile content. UIEvolution claims its platform delivers rich media content… Continue Reading
Life sciences briefing: Monday, Sept. 24, 2007
Featured companies: Adnexus Therapeutics, Bristol-Myers Squibb, Cellerix, Elixir Therapeutics, GenomeQuest, Intronn, JapanBridge, JenaValve, VirXsys, Ysios Capital
[NOTE: This item is a catchup daily briefing originally posted on 9/27/07. I've edited the item's timestamp to preserve the chronological order of the briefings. --D.P.H.]
Adnexus Thera cancels IPO, sells itself to Bristol-Myers for $430M — Waltham, Mass.-based Adnexus Therapeutics, a biotech pursuing drugs against cancer and other diseases, said it would cancel plans for its IPO and instead sell… Continue Reading